RNA - Avidity Biosciences, Inc.

Price Target Consensus

74.67

Consensus Target

96

High Target

72

Median Target

72

Low Target

Price Target News & Updates

Date	Analyst	Company	Price Target	News Title
2025-12-18	N/A	Evercore ISI	$72	Avidity Biosciences downgraded to In Line from Outperform at Evercore ISI
2025-10-28	Keay Nakae	Chardan Capital	$72	Avidity Biosciences downgraded to Neutral from Buy at Chardan
2025-10-28	Luca Issi	RBC Capital	$72	RBC Capital Downgrades Avidity Biosciences (RNA) to Sector Perform
2025-10-28	Keay Nakae	Loop Capital Markets	$72	Chardan Capital Markets Downgrades Avidity Biosciences (RNA) to Neutral
2025-10-27	Market Perform	Leerink Partners	$72	Avidity Biosciences downgraded to Market Perform from Outperform at Leerink
2025-10-27	Boobalan Pachaiyappan	Roth Capital	$72	Avidity Biosciences downgraded to Neutral from Buy at Roth Capital
2025-10-27	Market Perform	Bernstein	$72	Avidity Biosciences downgraded to Market Perform from Outperform at Bernstein
2025-10-27	N/A	H.C. Wainwright	$72	Avidity Biosciences downgraded to Neutral from Buy at H.C. Wainwright
2025-09-17	N/A	Roth Capital	$62	Avidity Biosciences initiated with a Buy at Roth Capital
2025-09-10	Eric Schmidt	Cantor Fitzgerald	$96	Avidity del-zota data 'highly encouraging,' says Cantor Fitzgerald